Elite in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. Noa Biran

Oncology | Hematology
HackenSack Meridian health
HMH - John Theurer Cancer Center - Hackensack
92 2nd Street, 
Hackensack, NJ 
Offers Telehealth

Elite in Relapsed Refractory Multiple Myeloma (RRMM)
HackenSack Meridian health
HMH - John Theurer Cancer Center - Hackensack
92 2nd Street, 
Hackensack, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Noa Biran is an Oncologist and a Hematologist in Hackensack, New Jersey. Dr. Biran is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). Her top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Plasmacytoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 62 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles and participated in 1 clinical trial in the study of Relapsed Refractory Multiple Myeloma (RRMM).

Graduate Institution
George Washington University School Of Medicine
Specialties
Oncology
Hematology
Licenses
Internal Medicine in NJ
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine
American Board Of Internal Medicine
Fellowships
Icahn School of Medicine At Mount Sinai
Hospital Affiliations
Hackensack University Medical Center
Southern Ocean Medical Center
Morristown Medical Center
Jersey Shore University Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Longevity Health Plan
  • MEDICARE SNP
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

HMH - John Theurer Cancer Center - Hackensack
92 2nd Street, Hackensack, NJ 7601.
Call: 551-996-8704
Other Locations
Astera Cancer Care
3 Progress Street, Suite 100, Edison, NJ 8820.
Call: 732-390-7750

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: TAK-573, Dexamethasone
Study Phase: Phase 1/Phase 2
Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Enrollment Status: Terminated
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drug: KPT-8602
Study Phase: Phase 1/Phase 2
A Phase 2B Study of Selinexor (KPT-330), in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma Relapsing on Current Therapy
A Phase 2B Study of Selinexor (KPT-330), in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma Relapsing on Current Therapy
Enrollment Status: Suspended
Publish Date: February 25, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone
Study Phase: Phase 2
A Multi-Center Phase 2 Study of Daratumumab With Pomalidomide and Dexamethasone in Combination With All-Transretinoic Acid in Patients With Multiple Myeloma Previously Exposed to Daratumumab-Based Regimens
A Multi-Center Phase 2 Study of Daratumumab With Pomalidomide and Dexamethasone in Combination With All-Transretinoic Acid in Patients With Multiple Myeloma Previously Exposed to Daratumumab-Based Regimens
Enrollment Status: Terminated
Publish Date: February 25, 2025
Intervention Type: Drug
Study Drugs: Daratumumab, Pomalidomide, All-Trans Retinoic Acid, Dexamethasone
Study Phase: Phase 2
(PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older
(PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older
Enrollment Status: Terminated
Publish Date: November 28, 2023
Intervention Type: Drug
Study Drugs: Melphalan, Bortezomib
Study Phase: Phase 2
View 5 Less Clinical Trials

62 Total Publications

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.
Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.
Journal: Leukemia & lymphoma
Published: December 02, 2025
View All 62 Publications
Similar Doctors
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Joshua R. Richter
Oncology | Hematology
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Joshua R. Richter
Oncology | Hematology

Icahn School Of Medicine At Mount Sinai

1 Gustave L Levy Pl, 
New York, NY 
 (8.4 miles away)
212-731-7650
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joshua Richter is an Oncologist and a Hematologist in New York, New York. Dr. Richter is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Secondary Immunodeficiency (SID), Bone Marrow Transplant, and Bone Marrow Aspiration.

Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Saad Z. Usmani
Hematology | Oncology | Transplant Surgery
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Saad Z. Usmani
Hematology | Oncology | Transplant Surgery

Memorial Hematology Lymphoma Group

1275 York Ave, 
New York, NY 
 (9.8 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Saad Usmani is a Hematologist and an Oncologist in New York, New York. Dr. Usmani is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Sundar Jagannath
Oncology
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Sundar Jagannath
Oncology

Icahn School Of Medicine At Mount Sinai

5 E 98th St, Suite 6, 
New York, NY 
 (8.4 miles away)
212-241-4812
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sundar Jagannath is an Oncologist in New York, New York. Dr. Jagannath is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Plasmacytoma, and Bone Marrow Aspiration.

VIEW MORE RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Biran's expertise for a condition
ConditionClose
  • Elite
  • Multiple Myeloma
    Dr. Biran is
    Elite
    . Learn about Multiple Myeloma.
    See more Multiple Myeloma experts
  • Relapsed Refractory Multiple Myeloma (RRMM)
    Dr. Biran is
    Elite
    . Learn about Relapsed Refractory Multiple Myeloma (RRMM).
    See more Relapsed Refractory Multiple Myeloma (RRMM) experts
  • Distinguished
  • Agranulocytosis
    Dr. Biran is
    Distinguished
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Bone Marrow Transplant
    Dr. Biran is
    Distinguished
    . Learn about Bone Marrow Transplant.
    See more Bone Marrow Transplant experts
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
    Dr. Biran is
    Distinguished
    . Learn about Monoclonal Gammopathy of Undetermined Significance (MGUS).
    See more Monoclonal Gammopathy of Undetermined Significance (MGUS) experts
  • Plasmacytoma
    Dr. Biran is
    Distinguished
    . Learn about Plasmacytoma.
    See more Plasmacytoma experts
  • Schnitzler Syndrome
    Dr. Biran is
    Distinguished
    . Learn about Schnitzler Syndrome.
    See more Schnitzler Syndrome experts
  • Smoldering Multiple Myeloma
    Dr. Biran is
    Distinguished
    . Learn about Smoldering Multiple Myeloma.
    See more Smoldering Multiple Myeloma experts
  • Advanced
  • Bone Marrow Aspiration
    Dr. Biran is
    Advanced
    . Learn about Bone Marrow Aspiration.
    See more Bone Marrow Aspiration experts
  • Chronic Familial Neutropenia
    Dr. Biran is
    Advanced
    . Learn about Chronic Familial Neutropenia.
    See more Chronic Familial Neutropenia experts
  • Severe Congenital Neutropenia
    Dr. Biran is
    Advanced
    . Learn about Severe Congenital Neutropenia.
    See more Severe Congenital Neutropenia experts
  • Waldenstrom Macroglobulinemia
    Dr. Biran is
    Advanced
    . Learn about Waldenstrom Macroglobulinemia.
    See more Waldenstrom Macroglobulinemia experts
  • Experienced
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Biran is
    Experienced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Biran is
    Experienced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Biran is
    Experienced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Anemia
    Dr. Biran is
    Experienced
    . Learn about Anemia.
    See more Anemia experts
  • B-Cell Lymphoma
    Dr. Biran is
    Experienced
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
  • Cardiac Amyloidosis
    Dr. Biran is
    Experienced
    . Learn about Cardiac Amyloidosis.
    See more Cardiac Amyloidosis experts
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.